# A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

> **NCT01669070** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF, 50 mcg
- **DRUG:** FF, 100 mcg
- **DRUG:** FF, 200 mcg
- **DRUG:** FF, 250 mcg

## Key facts

- **NCT ID:** NCT01669070
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-15
- **Primary completion:** 2012-11-16
- **Final completion:** 2012-11-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01669070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01669070, "A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01669070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*